Current State of the Art: Management of Higher Risk Myelodysplastic Syndromes
The higher risk myelodysplastic syndrome (MDS) patients, defined by the International Prognostic Scoring System (IPSS) as intermediate-2 or high-risk groups, compromise a third of MDS patients who have an expected survival of less than 1.5 years. Our ability to better define higher risk MDS improved with the proposal of new clinical risk models such as the revised IPSS and by integration of molecular data, including somatic gene mutations. Allogeneic hematopoietic stem-cell transplantation (AHSCT) remains the only curative option.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Rami S. Komrokji Tags: SOHO Supplement 2016 Source Type: research
More News: Genetics | Hematology | Leukemia | Lymphoma | Myelodysplastic Syndrome | Myeloma | Stem Cell Therapy | Stem Cells | Transplants